GENinCode (LSE:GENI) EV-to-Revenue : 4.60 (As of Jun. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, GENinCode's enterprise value is £9.94 Mil. GENinCode's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2.16 Mil. Therefore, GENinCode's EV-to-Revenue for today is 4.60.

The historical rank and industry rank for GENinCode's EV-to-Revenue or its related term are showing as below:

LSE:GENI' s EV-to-Revenue Range Over the Past 10 Years
Min: -9.22 Med: 1.2 Max: 43.28
Current: 4.6

During the past 5 years, the highest EV-to-Revenue of GENinCode was 43.28. The lowest was -9.22. And the median was 1.20.

LSE:GENI's EV-to-Revenue is ranked worse than
65.61% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.04 vs LSE:GENI: 4.60

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-24), GENinCode's stock price is £0.06875. GENinCode's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.02. Therefore, GENinCode's PS Ratio for today is 2.99.

GENinCode EV-to-Revenue Historical Data

The historical data trend for GENinCode's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode EV-to-Revenue Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

14.37

-1.38

1.30

GENinCode Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial			14.37	-	-1.38	-	1.30

Competitive Comparison of GENinCode's EV-to-Revenue

For the Diagnostics & Research subindustry, GENinCode's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where GENinCode's EV-to-Revenue falls into.

GENinCode EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

GENinCode's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	9.939	/	2.16
	=	4.60

GENinCode's current Enterprise Value is £9.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. GENinCode's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2.16 Mil.

GENinCode (LSE:GENI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

GENinCode's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.06875	/	0.023
	=	2.99

GENinCode's share price for today is £0.06875.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.02.

GENinCode EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of GENinCode's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode (LSE:GENI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.